Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Reduced expression of α-L-Fucosidase-1 (FUCA-1) predicts recurrence and shorter cancer specific survival in luminal B LN+ breast cancer patients.

Bonin S, Parascandolo A, Aversa C, Barbazza R, Tsuchida N, Castellone MD, Stanta G, Vecchio G.

Oncotarget. 2018 Feb 7;9(20):15228-15238. doi: 10.18632/oncotarget.24445. eCollection 2018 Mar 16.

2.

Antitumor efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models.

Della Corte CM, Ciaramella V, Cardone C, La Monica S, Alfieri R, Petronini PG, Malapelle U, Vigliar E, Pepe F, Troncone G, Castellone MD, Troiani T, Martinelli E, Ciardiello F, Morgillo F.

J Thorac Oncol. 2018 Mar 8. pii: S1556-0864(18)30181-3. doi: 10.1016/j.jtho.2018.02.025. [Epub ahead of print]

PMID:
29526823
3.

A dual mechanism of activation of the Sonic Hedgehog pathway in anaplastic thyroid cancer: crosstalk with RAS-BRAF-MEK pathway and ligand secretion by tumor stroma.

Parascandolo A, Laukkanen MO, De Rosa N, Ugolini C, Cantisani MC, Cirafici AM, Basolo F, Santoro M, Castellone MD.

Oncotarget. 2017 Dec 17;9(4):4496-4510. doi: 10.18632/oncotarget.23388. eCollection 2018 Jan 12.

4.

RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2).

Castellone MD, Melillo RM.

Endocr Relat Cancer. 2018 Feb;25(2):T105-T119. doi: 10.1530/ERC-17-0303. Epub 2017 Sep 20. Review.

5.

Human a-L-fucosidase-1 attenuates the invasive properties of thyroid cancer.

Vecchio G, Parascandolo A, Allocca C, Ugolini C, Basolo F, Moracci M, Strazzulli A, Cobucci-Ponzano B, Laukkanen MO, Castellone MD, Tsuchida N.

Oncotarget. 2017 Apr 18;8(16):27075-27092. doi: 10.18632/oncotarget.15635.

6.

Extracellular Superoxide Dismutase Expression in Papillary Thyroid Cancer Mesenchymal Stem/Stromal Cells Modulates Cancer Cell Growth and Migration.

Parascandolo A, Rappa F, Cappello F, Kim J, Cantu DA, Chen H, Mazzoccoli G, Hematti P, Castellone MD, Salvatore M, Laukkanen MO.

Sci Rep. 2017 Feb 20;7:41416. doi: 10.1038/srep41416.

7.

TGF-beta1, WNT, and SHH signaling in tumor progression and in fibrotic diseases.

Castellone MD, Laukkanen MO.

Front Biosci (Schol Ed). 2017 Jan 1;9:31-45. Review.

PMID:
27814572
8.

A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability.

Cantisani MC, Parascandolo A, Perälä M, Allocca C, Fey V, Sahlberg N, Merolla F, Basolo F, Laukkanen MO, Kallioniemi OP, Santoro M, Castellone MD.

Oncotarget. 2016 May 10;7(19):28510-22. doi: 10.18632/oncotarget.8577.

9.

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.

Della Corte CM, Ciaramella V, Di Mauro C, Castellone MD, Papaccio F, Fasano M, Sasso FC, Martinelli E, Troiani T, De Vita F, Orditura M, Bianco R, Ciardiello F, Morgillo F.

Oncotarget. 2016 Jan 26;7(4):4265-78. doi: 10.18632/oncotarget.6559.

10.

Hijacking the Hedgehog Pathway in Cancer Therapy.

Laukkanen MO, Castellone MD.

Anticancer Agents Med Chem. 2016;16(3):309-17. Review.

PMID:
26443025
11.
12.

Sonic Hedgehog in SCLC.

Laukkanen MO, Gutkind JS, Castellone MD.

Aging (Albany NY). 2015 Sep;7(9):605-6. No abstract available.

13.

Extracellular superoxide dismutase regulates the expression of small gtpase regulatory proteins GEFs, GAPs, and GDI.

Laukkanen MO, Cammarota F, Esposito T, Salvatore M, Castellone MD.

PLoS One. 2015 Mar 9;10(3):e0121441. doi: 10.1371/journal.pone.0121441. eCollection 2015.

14.

NCOA4 transcriptional coactivator inhibits activation of DNA replication origins.

Bellelli R, Castellone MD, Guida T, Limongello R, Dathan NA, Merolla F, Cirafici AM, Affuso A, Masai H, Costanzo V, Grieco D, Fusco A, Santoro M, Carlomagno F.

Mol Cell. 2014 Jul 3;55(1):123-37. doi: 10.1016/j.molcel.2014.04.031. Epub 2014 Jun 5.

15.

Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma.

Castellone MD, Laukkanen MO, Teramoto H, Bellelli R, Alì G, Fontanini G, Santoro M, Gutkind JS.

Oncogene. 2015 Mar 26;34(13):1679-87. doi: 10.1038/onc.2014.104. Epub 2014 Apr 21.

16.

Extracellular superoxide dismutase induces mouse embryonic fibroblast proliferative burst, growth arrest, immortalization, and consequent in vivo tumorigenesis.

Castellone MD, Langella A, Cantara S, Laurila JP, Laatikainen LE, Bellelli R, Pacini F, Salvatore M, Laukkanen MO.

Antioxid Redox Signal. 2014 Oct 1;21(10):1460-74. doi: 10.1089/ars.2013.5475. Epub 2014 Feb 19.

PMID:
24328532
17.

Brief report: Mesenchymal stromal cell atrophy in coculture increases aggressiveness of transformed cells.

Castellone MD, Laatikainen LE, Laurila JP, Langella A, Hematti P, Soricelli A, Salvatore M, Laukkanen MO.

Stem Cells. 2013 Jun;31(6):1218-23. doi: 10.1002/stem.1361.

18.

FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma.

Bellelli R, Castellone MD, Garcia-Rostan G, Ugolini C, Nucera C, Sadow PM, Nappi TC, Salerno P, Cantisani MC, Basolo F, Gago TA, Salvatore G, Santoro M.

Endocr Relat Cancer. 2012 Sep 21;19(5):695-710. doi: 10.1530/ERC-12-0031. Print 2012 Oct.

19.

CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cells.

De Falco V, Tamburrino A, Ventre S, Castellone MD, Malek M, Manié SN, Santoro M.

Cancer Res. 2012 Mar 15;72(6):1449-58. doi: 10.1158/0008-5472.CAN-11-3320. Epub 2012 Jan 23.

20.

SOD3 decreases ischemic injury derived apoptosis through phosphorylation of Erk1/2, Akt, and FoxO3a.

Laatikainen LE, Incoronato M, Castellone MD, Laurila JP, Santoro M, Laukkanen MO.

PLoS One. 2011;6(8):e24456. doi: 10.1371/journal.pone.0024456. Epub 2011 Aug 31.

21.

Biomarkers in thyroid tumor research: new diagnostic tools and potential targets of molecular-based therapy.

Gimm O, Castellone MD, Hoang-Vu C, Kebebew E.

J Thyroid Res. 2011;2011:631593. doi: 10.4061/2011/631593. Epub 2012 Feb 16. No abstract available.

22.

Extracellular superoxide dismutase is a thyroid differentiation marker down-regulated in cancer.

Laatikainen LE, Castellone MD, Hebrant A, Hoste C, Cantisani MC, Laurila JP, Salvatore G, Salerno P, Basolo F, Näsman J, Dumont JE, Santoro M, Laukkanen MO.

Endocr Relat Cancer. 2010 Aug 16;17(3):785-96. doi: 10.1677/ERC-10-0021. Print 2010 Sep.

23.

A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization.

Castellone MD, Verrienti A, Magendra Rao D, Sponziello M, Fabbro D, Muthu M, Durante C, Maranghi M, Damante G, Pizzolitto S, Costante G, Russo D, Santoro M, Filetti S.

Clin Endocrinol (Oxf). 2010 Oct;73(4):529-34. doi: 10.1111/j.1365-2265.2009.03757.x.

PMID:
20039896
24.

Human embryonic stem cell-derived mesenchymal stromal cell transplantation in a rat hind limb injury model.

Laurila JP, Laatikainen L, Castellone MD, Trivedi P, Heikkila J, Hinkkanen A, Hematti P, Laukkanen MO.

Cytotherapy. 2009;11(6):726-37. doi: 10.3109/14653240903067299.

25.

Thyroid cancer and inflammation.

Guarino V, Castellone MD, Avilla E, Melillo RM.

Mol Cell Endocrinol. 2010 May 28;321(1):94-102. doi: 10.1016/j.mce.2009.10.003. Epub 2009 Oct 14. Review.

PMID:
19835928
26.

SOD3 reduces inflammatory cell migration by regulating adhesion molecule and cytokine expression.

Laurila JP, Laatikainen LE, Castellone MD, Laukkanen MO.

PLoS One. 2009 Jun 4;4(6):e5786. doi: 10.1371/journal.pone.0005786.

27.

The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation.

Castellone MD, De Falco V, Rao DM, Bellelli R, Muthu M, Basolo F, Fusco A, Gutkind JS, Santoro M.

Cancer Res. 2009 Mar 1;69(5):1867-76. doi: 10.1158/0008-5472.CAN-08-1982. Epub 2009 Feb 17.

28.

Extracellular superoxide dismutase is a growth regulatory mediator of tissue injury recovery.

Laurila JP, Castellone MD, Curcio A, Laatikainen LE, Haaparanta-Solin M, Gronroos TJ, Marjamaki P, Martikainen S, Santoro M, Laukkanen MO.

Mol Ther. 2009 Mar;17(3):448-54. doi: 10.1038/mt.2008.282. Epub 2008 Dec 23.

29.

Receptor tyrosine kinase inhibitors in thyroid cancer.

Castellone MD, Carlomagno F, Salvatore G, Santoro M.

Best Pract Res Clin Endocrinol Metab. 2008 Dec;22(6):1023-38. doi: 10.1016/j.beem.2008.09.012. Review.

PMID:
19041829
30.

Dysregulated RET signaling in thyroid cancer.

Castellone MD, Santoro M.

Endocrinol Metab Clin North Am. 2008 Jun;37(2):363-74, viii. doi: 10.1016/j.ecl.2008.02.006. Review.

PMID:
18502331
31.

Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer.

De Falco V, Guarino V, Avilla E, Castellone MD, Salerno P, Salvatore G, Faviana P, Basolo F, Santoro M, Melillo RM.

Cancer Res. 2007 Dec 15;67(24):11821-9.

32.

OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome.

Staibano S, Merolla F, Testa D, Iovine R, Mascolo M, Guarino V, Castellone MD, Di Benedetto M, Galli V, Motta S, Melillo RM, De Rosa G, Santoro M, Celetti A.

Br J Cancer. 2007 Dec 3;97(11):1545-51. Epub 2007 Nov 6.

33.

A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma.

Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C, Miccoli P, Basolo F, Castellone MD, Cirafici AM, Melillo RM, Fusco A, Bittner ML, Santoro M.

Cancer Res. 2007 Nov 1;67(21):10148-58.

34.

Rac inhibits thrombin-induced Rho activation: evidence of a Pak-dependent GTPase crosstalk.

Rosenfeldt H, Castellone MD, Randazzo PA, Gutkind JS.

J Mol Signal. 2006 Dec 6;1:8.

35.

RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase.

De Falco V, Castellone MD, De Vita G, Cirafici AM, Hershman JM, Guerrero C, Fusco A, Melillo RM, Santoro M.

Cancer Res. 2007 Jan 1;67(1):381-90.

36.

Cyclooxygenase-2 and colorectal cancer chemoprevention: the beta-catenin connection.

Castellone MD, Teramoto H, Gutkind JS.

Cancer Res. 2006 Dec 1;66(23):11085-8. Review.

37.

Gene expression changes in a patient presenting nonleukaemic nasal granulocytic sarcoma to acute myelogenous leukaemia using 40 K cDNA microarray.

Teramoto H, Miwa H, Patel V, Letwin N, Castellone MD, Imai N, Shikami M, Imamura A, Gutkind JS, Nitta M, Lee NH.

Clin Lab Haematol. 2006 Aug;28(4):262-6.

PMID:
16898967
38.

Robo4 signaling in endothelial cells implies attraction guidance mechanisms.

Kaur S, Castellone MD, Bedell VM, Konar M, Gutkind JS, Ramchandran R.

J Biol Chem. 2006 Apr 21;281(16):11347-56. Epub 2006 Feb 15.

39.

Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness.

Celetti A, Testa D, Staibano S, Merolla F, Guarino V, Castellone MD, Iovine R, Mansueto G, Somma P, De Rosa G, Galli V, Melillo RM, Santoro M.

Clin Cancer Res. 2005 Nov 15;11(22):8019-27.

40.

Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis.

Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS.

Science. 2005 Dec 2;310(5753):1504-10. Epub 2005 Nov 17.

41.

Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1.

Monje P, Hernández-Losa J, Lyons RJ, Castellone MD, Gutkind JS.

J Biol Chem. 2005 Oct 21;280(42):35081-4. Epub 2005 Aug 25.

42.

Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness.

Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, De Falco V, Celetti A, Giannini R, Basolo F, Melillo RM, Santoro M.

J Clin Endocrinol Metab. 2005 Sep;90(9):5270-8. Epub 2005 Jul 5.

PMID:
15998773
43.

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.

Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M.

J Clin Invest. 2005 Apr;115(4):1068-81. Epub 2005 Mar 10. Retraction in: J Clin Invest. 2016 Apr 1;126(4):1603.

44.

Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12.

Teramoto H, Castellone MD, Malek RL, Letwin N, Frank B, Gutkind JS, Lee NH.

Oncogene. 2005 Jan 13;24(3):489-501.

PMID:
15516973
45.
46.

Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas.

Castellone MD, Guarino V, De Falco V, Carlomagno F, Basolo F, Faviana P, Kruhoffer M, Orntoft T, Russell JP, Rothstein JL, Fusco A, Santoro M, Melillo RM.

Oncogene. 2004 Aug 5;23(35):5958-67.

PMID:
15184868
47.

Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells.

Castellone MD, Celetti A, Guarino V, Cirafici AM, Basolo F, Giannini R, Medico E, Kruhoffer M, Orntoft TF, Curcio F, Fusco A, Melillo RM, Santoro M.

Oncogene. 2004 Mar 18;23(12):2188-96.

PMID:
14981541
48.

Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors.

Russell JP, Shinohara S, Melillo RM, Castellone MD, Santoro M, Rothstein JL.

Oncogene. 2003 Jul 17;22(29):4569-77.

PMID:
12881713
49.

Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase.

Andreozzi F, Melillo RM, Carlomagno F, Oriente F, Miele C, Fiory F, Santopietro S, Castellone MD, Beguinot F, Santoro M, Formisano P.

Oncogene. 2003 May 15;22(19):2942-9.

PMID:
12771945
50.

Identification of H-Ras, RhoA, Rac1 and Cdc42 responsive genes.

Teramoto H, Malek RL, Behbahani B, Castellone MD, Lee NH, Gutkind JS.

Oncogene. 2003 May 1;22(17):2689-97.

PMID:
12730683

Supplemental Content

Loading ...
Support Center